Safety and Efficacy of Tenapanor for Long-term Serum Phosphate Control in Maintenance Dialysis: A 52-Week Randomized Phase 3 Trial (PHREEDOM).

Geoffrey A BlockAnthony J BleyerArnold L SilvaDaniel E WeinerRobert I LynnYang YangDavid P RosenbaumGlenn M Chertow

Published in: Kidney360 (2021)

Tenapanor reduced serum phosphate concentrations and maintained control of serum phosphate in participants receiving maintenance dialysis, with an acceptable safety and tolerability profile.

Keyphrases

chronic kidney disease
open label
placebo controlled
double blind
end stage renal disease
clinical trial
randomized controlled trial
peritoneal dialysis
study protocol